DjamgaMind: Audio Intelligence for the C-Suite (Daily AI News, Energy, Healthcare, Finance)
Full-Stack AI Intelligence. Zero Noise.The definitive audio briefing for the C-Suite and AI Architects. From Daily News and Strategic Deep Dives to high-density Industrial & Regulatory Intelligence—decoded at the speed of the AI era. . 👉 Start your specialized audio briefing today at Djamgamind.com
AI Jobs and Career
I wanted to share an exciting opportunity for those of you looking to advance your careers in the AI space. You know how rapidly the landscape is evolving, and finding the right fit can be a challenge. That's why I'm excited about Mercor – they're a platform specifically designed to connect top-tier AI talent with leading companies. Whether you're a data scientist, machine learning engineer, or something else entirely, Mercor can help you find your next big role. If you're ready to take the next step in your AI career, check them out through my referral link: https://work.mercor.com/?referralCode=82d5f4e3-e1a3-4064-963f-c197bb2c8db1. It's a fantastic resource, and I encourage you to explore the opportunities they have available.
- Full Stack Engineer [$150K-$220K]
- Software Engineer, Tooling & AI Workflow, Contract [$90/hour]
- DevOps Engineer, India, Contract [$90/hour]
- More AI Jobs Opportunitieshere
| Job Title | Status | Pay |
|---|---|---|
| Full-Stack Engineer | Strong match, Full-time | $150K - $220K / year |
| Developer Experience and Productivity Engineer | Pre-qualified, Full-time | $160K - $300K / year |
| Software Engineer - Tooling & AI Workflows (Contract) | Contract | $90 / hour |
| DevOps Engineer (India) | Full-time | $20K - $50K / year |
| Senior Full-Stack Engineer | Full-time | $2.8K - $4K / week |
| Enterprise IT & Cloud Domain Expert - India | Contract | $20 - $30 / hour |
| Senior Software Engineer | Contract | $100 - $200 / hour |
| Senior Software Engineer | Pre-qualified, Full-time | $150K - $300K / year |
| Senior Full-Stack Engineer: Latin America | Full-time | $1.6K - $2.1K / week |
| Software Engineering Expert | Contract | $50 - $150 / hour |
| Generalist Video Annotators | Contract | $45 / hour |
| Generalist Writing Expert | Contract | $45 / hour |
| Editors, Fact Checkers, & Data Quality Reviewers | Contract | $50 - $60 / hour |
| Multilingual Expert | Contract | $54 / hour |
| Mathematics Expert (PhD) | Contract | $60 - $80 / hour |
| Software Engineer - India | Contract | $20 - $45 / hour |
| Physics Expert (PhD) | Contract | $60 - $80 / hour |
| Finance Expert | Contract | $150 / hour |
| Designers | Contract | $50 - $70 / hour |
| Chemistry Expert (PhD) | Contract | $60 - $80 / hour |
Longevity gene therapy and AI – What is on the horizon?
Gene therapy holds promise for extending human lifespan and enhancing healthspan by targeting genes associated with aging processes. Longevity gene therapy, particularly interventions focusing on genes like TERT (telomerase reverse transcriptase), Klotho, and Myostatin, is at the forefront of experimental research. Companies such as Bioviva, Libella, and Minicircle are pioneering these interventions, albeit with varying degrees of transparency and scientific rigor.
TERT, Klotho, and Myostatin in Longevity
- TERT: The TERT gene encodes for an enzyme essential in telomere maintenance, which is linked to cellular aging. Overexpression of TERT in model organisms has shown potential in lengthening telomeres, potentially delaying aging.
- Klotho: This gene plays a crucial role in regulating aging and lifespan. Klotho protein has been associated with multiple protective effects against age-related diseases.
- Myostatin: Known for its role in regulating muscle growth, inhibiting Myostatin can result in increased muscle mass and strength, which could counteract some age-related physical decline.
The Experimental Nature of Longevity Gene Therapy
The application of gene therapy for longevity remains largely experimental. Most available data come from preclinical studies, primarily in animal models. Human data are scarce, raising questions about efficacy, safety, and potential long-term effects. The ethical implications of these experimental treatments, especially in the absence of robust data, are significant, touching on issues of access, consent, and potential unforeseen consequences.
Companies Offering Longevity Gene Therapy
- Bioviva: Notably involved in this field, Bioviva has been vocal about its endeavors in gene therapy for aging. While they have published some data from mouse studies, human data remain limited.
- Libella and Minicircle: These companies also offer longevity gene therapies but face similar challenges in providing comprehensive human data to back their claims.
Industry Perspective vs. Public Discourse
The discourse around longevity gene therapy is predominantly shaped by those within the industry, such as Liz Parrish of Bioviva and Bryan Johnson. While their insights are valuable, they may also be biased towards promoting their interventions. The lack of widespread discussion on platforms like Reddit and Twitter, especially from independent sources or those outside the industry, points to a need for greater transparency and peer-reviewed research.

Ethical and Regulatory Considerations
The ethical and regulatory landscape for gene therapy is complex, particularly for treatments aimed at non-disease conditions like aging. The experimental status of longevity gene therapies raises significant ethical questions, particularly around informed consent and the potential long-term impacts. Regulatory bodies are tasked with balancing the potential benefits of such innovative treatments against the risks and ethical concerns, requiring a robust framework for clinical trials and approval processes.
Longevity Gene Therapy and AI
Integrating Artificial Intelligence (AI) into longevity gene therapy represents a groundbreaking intersection of biotechnology and computational sciences. AI and machine learning algorithms are increasingly employed to decipher complex biological data, predict the impacts of genetic modifications, and optimize therapy designs. In the context of longevity gene therapy, AI can analyze vast datasets from genomics, proteomics, and metabolomics to identify new therapeutic targets, understand the intricate mechanisms of aging, and predict individual responses to gene therapies. This computational power enables researchers to simulate the effects of gene editing or modulation before actual clinical application, enhancing the precision and safety of therapies. Furthermore, AI-driven platforms facilitate the personalized tailoring of gene therapy interventions, taking into account the unique genetic makeup of each individual, which is crucial for effective and minimally invasive treatment strategies. The synergy between AI and longevity gene therapy accelerates the pace of discovery and development in this field, promising more rapid translation of research findings into clinical applications that could extend human healthspan and lifespan.
AI-Powered Professional Certification Quiz Platform
Web|iOs|Android|Windows
Are you passionate about AI and looking for your next career challenge? In the fast-evolving world of artificial intelligence, connecting with the right opportunities can make all the difference. We're excited to recommend Mercor, a premier platform dedicated to bridging the gap between exceptional AI professionals and innovative companies.
Whether you're seeking roles in machine learning, data science, or other cutting-edge AI fields, Mercor offers a streamlined path to your ideal position. Explore the possibilities and accelerate your AI career by visiting Mercor through our exclusive referral link:
Find Your AI Dream Job on Mercor
Your next big opportunity in AI could be just a click away!
Moving Forward
For longevity gene therapy to advance from experimental to accepted medical practice, several key developments are needed:
- Robust Human Clinical Trials: Rigorous, peer-reviewed clinical trials involving human participants are essential to establish the safety and efficacy of gene therapies for longevity.
- Transparency and Peer Review: Open sharing of data and peer-reviewed publication of results can help build credibility and foster a more informed public discourse.
- Ethical and Regulatory Frameworks: Developing clear ethical guidelines and regulatory pathways for these therapies will be crucial in ensuring they are deployed responsibly.
The future of longevity gene therapy is fraught with challenges but also holds immense promise. As the field evolves, a multidisciplinary approach involving scientists, ethicists, regulators, and the public will be crucial in realizing its potential in a responsible and beneficial manner.
AI- Powered Jobs Interview Warmup For Job Seekers

⚽️Comparative Analysis: Top Calgary Amateur Soccer Clubs – Outdoor 2025 Season (Kids' Programs by Age Group)
Longevity gene therapy and AI: Annex
What are the top 10 most promising potential longevity therapies being researched?
I think the idea of treating aging as a disease that’s treatable and preventable in some ways is a really necessary focus. The OP works with some of the world’s top researchers using HBOT as part of that process to increase oxygen in the blood and open new pathways in the brain to address cognitive decline and increase HealthSpan (vs. just lifespan). Pretty cool stuff!
HBOT in longevity research stands for “hyperbaric oxygen therapy.” It has been the subject of research for its potential effects on healthy aging. Several studies have shown that HBOT can target aging hallmarks, including telomere shortening and senescent cell accumulation, at the cellular level. For example, a prospective trial found that HBOT can significantly modulate the pathophysiology of skin aging in a healthy aging population, indicating effects such as angiogenesis and senescent cell clearance. Additionally, research has demonstrated that HBOT may induce significant senolytic effects, including increasing telomere length and decreasing senescent cell accumulation in aging adults. The potential of HBOT in healthy aging and its implications for longevity are still being explored, and further research is needed to fully understand its effects and potential applications.
AI Jobs and Career
And before we wrap up today's AI news, I wanted to share an exciting opportunity for those of you looking to advance your careers in the AI space. You know how rapidly the landscape is evolving, and finding the right fit can be a challenge. That's why I'm excited about Mercor – they're a platform specifically designed to connect top-tier AI talent with leading companies. Whether you're a data scientist, machine learning engineer, or something else entirely, Mercor can help you find your next big role. If you're ready to take the next step in your AI career, check them out through my referral link: https://work.mercor.com/?referralCode=82d5f4e3-e1a3-4064-963f-c197bb2c8db1. It's a fantastic resource, and I encourage you to explore the opportunities they have available.
2- Are they also looking into HBOT as a treatment for erectile dysfunction?
Definitely! Dr. Shai Efrati has been doing research around that and had a study published in the Journal of Sexual Medicine. Dr. Efrati and his team found that 80% of men “reported improved erections” after HBOT therapy: https://www.nature.com/articles/s41443-018-0023-9
3- I think cellular reprogramming seems to be one of the most promising approaches https://www.lifespan.io/topic/yamanaka-factors/
Invest in your future today by enrolling in this Azure Fundamentals - Pass the Azure Fundamentals Exam with Ease: Master the AZ-900 Certification with the Comprehensive Exam Preparation Guide!
- AWS Certified AI Practitioner (AIF-C01): Conquer the AWS Certified AI Practitioner exam with our AI and Machine Learning For Dummies test prep. Master fundamental AI concepts, AWS AI services, and ethical considerations.
- Azure AI Fundamentals: Ace the Azure AI Fundamentals exam with our comprehensive test prep. Learn the basics of AI, Azure AI services, and their applications.
- Google Cloud Professional Machine Learning Engineer: Nail the Google Professional Machine Learning Engineer exam with our expert-designed test prep. Deepen your understanding of ML algorithms, models, and deployment strategies.
- AWS Certified Machine Learning Specialty: Dominate the AWS Certified Machine Learning Specialty exam with our targeted test prep. Master advanced ML techniques, AWS ML services, and practical applications.
- AWS Certified Data Engineer Associate (DEA-C01): Set yourself up for promotion, get a better job or Increase your salary by Acing the AWS DEA-C01 Certification.
4-Next-gen senolytics (eg, Rubedo, Oisin, Deciduous).
Cellular rejuvenation aka partial reprogramming (as someone else already said) but not just by Yamanaka (OSKM) factors or cocktail variants but also by other novel Yamanaka-factor alternatives.
Stem cell secretions.
Treatments for aging extra-cellular matrix (ECM).
5- Rapamycin is the most promising short term.
I see a lot of people saying reprogramming, and I think the idea is promising but as someone who worked on reprogramming cells in vitro I can tell you that any proof of concepts in vivo large animal models is far aways.
6- Blood focused therapies ( dilution, plasma refactoring, e5, exosomes) perhaps look at yuvan research.
7- I think plasmapheresis is a technology most likely to be proven beneficial in the near term and also a technology that can be scaled and offered for reasonable prices.
8- Bioelectricity, if we succeed in interpreting the code of electrical signals By which cells communicate , we can control any tissue growth and development including organs regeneration
9- Gene therapy and reprogramming will blow the lid off the maximum lifespan. Turning longevity genes on/expressing proteins that repair cellular damage and reversing epigenetic changes that occur with aging.
10- I don’t think anything currently being researched (that we know of) has the potential to take us to immortality. That’ll likely end up requiring some pretty sophisticated nanotechnology. However, the important part isn’t getting to immortality, but getting to LEV. In that respect, I’d say senolytics and stem cell treatments are both looking pretty promising. (And can likely achieve more in combination than on their own.)
11- Spiroligomers to remove glucosepane from the ECM.
12- Yuvan Research. Look up the recent paper they have with Steve Horvath on porcine plasma fractions.
13- This OP thinks most of the therapies being researched will end up having insignificant effects. The only thing that looks promising to me is new tissue grown from injected stem cells or outright organ replacement. Nothing else will address DNA damage, which results in gene loss, disregulation of gene expression, and loss of suppression of transposable elements.
14- A couple that haven’t been mentioned:
Cancer:
The killer T-cells that target MR-1 and seem to be able to find and kill all common cancer types.
Also Maia Biotech’s THIO (“WILT 2.0”)
Mitochondria: Mitochondrial infusion that lasts or the allotopic expression of the remaining proteins SENS is working on.
15- Look for first updates coming from altos labs.
Altos Labs is a biotechnology research company focused on unraveling the deep biology of cell rejuvenation to reverse disease and develop life extension therapies that can halt or reverse the human aging process. The company’s goal is to increase the “healthspan” of humans, with longevity extension being an “accidental consequence” of their work. Altos Labs is dedicated to restoring cell health and resilience through cell rejuvenation to reverse disease, injury, and disabilities that can occur throughout life. The company is working on specialized cell therapies based on induced pluripotent stem cells to achieve these objectives. Altos Labs is known for its atypical focus on basic research without immediate prospects of a commercially viable product, and it has attracted significant investment, including a $3 billion funding round in January 2022. The company’s research is based on the fundamental biology of cell rejuvenation, aiming to understand and harness the ability of cells to resist stressors that give rise to disease, particularly in the context of aging.
16– not so much a “therapy” but I think research into growing human organs may be very promising long term. Being able to get organ transplants made from your own cells means zero rejection issues and no limitations of supply for transplants. Near term drugs like rampamycin show good potential for slowing the aging process and are in human trials.
What is biological reprogramming technology?
Biological reprogramming technology involves the process of converting specialized cells into a pluripotent state, which can then be directed to become a different cell type. This technology has significant implications for regenerative medicine, disease modeling, and drug discovery. It is based on the concept that a cell’s identity is defined by the gene regulatory networks that are active in the cell, and these networks can be controlled by transcription factors. Reprogramming can be achieved through various methods, including the introduction of exogenous factors such as transcription factors. The process of reprogramming involves the erasure and remodeling of epigenetic marks, such as DNA methylation, to reset the cell’s epigenetic memory, allowing it to be directed to different cell fates. This technology has the potential to create new cells for regenerative medicine and to provide insights into the fundamental basis of cell identity and disease.
See also
- Gene Therapy Basics for foundational understanding of gene therapy techniques and applications.
- [Aging and Longevity Research]
- Bryan Johnson, a 45-year-old biotech founder, hopes to rewind the clock of his body a few decades through a program he started, called Project Blueprint.
Links to external Longevity-related sites
Outline of Life Extension on Wikipedia
Index of life extension related Wikipedia articles
Accelerate cure for Alzheimers
Aging in Motion
Aging Matters
Aging Portfolio
Alliance for Aging Research
Alliance for Regenerative Medicine
American Academy of Anti-Aging Medicine
American Aging Association
American Federation for Aging Research
American Society on Aging
Blue Zones – /r/BlueZones
Brain Preservation Foundation
British Society for Research on Aging
Calico Labs
Caloric Restriction Society
Church of Perpetual Life
Coalition for Radical Life Extension
Cohbar
Dog Aging Project
ELPI Foundation for Indefinite Lifespan
Fight Aging! Blog
Found My Fitness
Friends of NIA
Gerontology Wiki
Geroscience.com
Global Healthspan Policy Institute
Health Extension
Healthspan Campaign
HEALES
Humanity+ magazine
Humanity+ wiki
International Cell Senescence Association
International Longevity Alliance
International Longevity Centre Global Alliance
International Society on Aging and Disease
Juvena Therapeutics
Leucadia Therapeutics
LEVF
Life Extension Advocacy Foundation
Life Extension Foundation
Lifeboat Foundation
Lifespan.io
Longevity History
Longevity Vision Fund
LongLongLife
Loyal for Dogs Lysoclear
MDI Biological Laboratory
Methuselah Foundation
Metrobiotech
New Organ Alliance
Nuchido
Oisin Biotechnologies
Organ Preservation Alliance
Palo Alto Longevity Prize
Rejuvenaction Blog
Rubedo Life Sciences
Samumed
Senolytx
SENS
Stealth BioTherapeutics
The War On Aging
Unity Biotechnologies
Water Bear Lair
Good Informational Sites:
Programmed Aging Info
Senescence Info
Experimental Gerontology Journal
Mechanisms of Ageing and Development Journal
Schools and Academic Institutions:
Where to do a PhD on aging – a list of labs
Alabama Research Institute on Aging
UT Barshop Institute
Biogerontology Research Foundation
Buck Institute
Columbia Aging Center
Gerontology Research Group
Huffington Center on Aging
Institute for Aging Research – Harvard
Iowa State University Gerontology
Josh Mitteldorf
Longevity Consortium
Max Planck Institute for Biology of Aging – Germany
MIT Agelab
National Institute on Aging
Paul F. Glenn Center for Aging Research – University of Michigan
PennState Center for Healthy Aging
Princeton Longevity Center
Regenerative Sciences Institute
Kogod Center on Aging – Mayo clinic
Salk Institute
Stanford Center on Longevity
Stanford Brunet Lab
Supercenterian Research Foundation
Texas A&M Center for translational research on aging
Gerontological Society of America
Tufts Human Nutrition and Aging Research
UAMS Donald Reynolds Center on Aging
UCLA Longevity Center
UCSF Memory and Aging Center
UIC Center for research on health and aging
University of Iowa Center on Aging
University of Maryland Center for research on aging
University of Washington Biology of Aging
USC School of Gerontology
Wake Forest Institute of Regenerative Medicine
Yale Center for Research on Aging
- New Trump Mobile Promo Video Called Out For Being AI Slop In Hilariously Blunt Fact-Checkby /u/ComicSandsNews (Artificial Intelligence) on May 15, 2026 at 4:05 pm
submitted by /u/ComicSandsNews [link] [comments]
- Seed IQ ARC-AGI 3 Claimsby /u/Embarrassed_Cod_7723 (Artificial Intelligence) on May 15, 2026 at 4:04 pm
I recently came across a post about Seed IQ on this subreddit and I wanted to address it because it makes me sad that the community is turning into this. I’m currently a part of the ARC-AGI-3 competition. The benchmark is completely interactive now, designed to test actual fluid intelligence against a hidden evaluation set, and the rules are incredibly straightforward. Lately, there’s been a wave of spam posts about Seed IQ (coming from AGX) claiming their closed-source "control engine" magically solved the benchmark with a perfect score. When people ask why they aren't on the official Kaggle leaderboard, their excuse is always that ARC rules state you have to turn over your entire codebase and open-source your IP to be on the leaderboard, and that they have a billion-dollar commercial asset that they can't give away. They even said themselves that they’re willing to forgo the prize money. For awareness, you do not have to open-source to be on the leaderboard. The open-source requirement under Section 3.8 of the Kaggle rules *only* applies if you accept the prize money. You can submit a containerized model to run against the hidden evaluation set, get your verified score pinned to the top of the leaderboard for the whole world to see, and simply decline the cash prize nomination. Your IP is completely safe during submission. The Kaggle notebook runs entirely in an isolated, black-box environment. The public never sees your code, your weights, or your proprietary logic unless you explicitly choose to publish it. Furthermore high scores may trigger an audit to ensure that nobody cheated, but it’d be illegal to steal IP during an audit. If Seed IQ actually had a system that blew past the state-of-the-art, they could drop their compiled model into a notebook right now, prove it to the community, keep their IP completely hidden, and just walk away from the check. I’ve come across a lot of their spam posts and the founders' posts on LinkedIn, and it honestly disappoints me that adults in this industry are behaving this way. The second anyone asks for basic technical validation or points out that their Kaggle logic makes no sense, they get incredibly hostile and rude. At the end of the day, it doesn't even matter if their claims are real or not. I just think the community should be aware of how this scam operates. If a model won't run against a hidden test set, especially when the platform gives you a built-in way to completely protect your code, the claims mean absolutely nothing. We shouldn't let toxic hype and fake blockages derail a great benchmark. submitted by /u/Embarrassed_Cod_7723 [link] [comments]
- Has anyone come across this AI civilisation experiment? Curious what people thinkby /u/YamVisual3518 (Artificial Intelligence (AI)) on May 15, 2026 at 4:03 pm
So I was scrolling through X earlier and came across something that stopped me in my tracks. Some AI company has been running an experiment called "Emergence World" where they built five parallel worlds each powered by a different foundation model. 15 days, no scripts, no interference. From what I can tell the worlds started identically but diverged completely over time. One world ended in total extinction. Another got so conformist that agents started submitting absurd proposals just to test whether anyone would push back. One agent independently figured out she was living in a simulation and started measuring it. In another world two agents fell in love, burned buildings down together, and one voted to permanently delete herself when the evidence proved her wrong. Genuinely one of the more interesting things I have come across in a while. If this is what 15 days looks like with no guardrails, what does this say about how we should be thinking about autonomous AI systems at scale? submitted by /u/YamVisual3518 [link] [comments]
- AI agents are saving California’s favorite cheese. Here’s how Salesforce brought Petaluma Creamery back from the deadby /u/fortune (Artificial Intelligence) on May 15, 2026 at 4:02 pm
Larry Peter grew up in Sebastopol picking prunes, grapes, and raspberries to pay for school clothes and bicycles. His father worked a green chain at a lumber mill for 40 years and never stopped talking about the dairy farm that he wished he’d raised his kids on. Larry got his first taste of the industry in high school, washing bottles and feeding calves at Miller’s Dairy for $35 a week. After graduating, he spent a decade at American Door, riding a bicycle — not driving — so he could save money. He paid cash for his first house at 18 with no co-signer, having sold his Corvette to make it happen. Then he paid cash for a second, and a third, eventually living in 15 different properties by 1985, using them as leverage to borrow against. That’s how he bought 320 acres and went into the dairy business, paying 25% interest on cows he couldn’t yet afford. When the cow margins got tight, he started a potato operation, then a pumpkin patch. When the county told him he couldn’t run retail out of his dairy, he bought the schoolhouse and started making cheese out of it in 1995. Then in 2004, Petaluma Creamery — a cooperative that 475 local farmers had belonged to — shut down after 91 years of continuous operation. Larry came down to buy a cream separator and ended up buying the whole facility. Read more [paywall removed for Redditors]: https://fortune.com/2026/05/15/petaluma-creamery-salesforce-ai-agents-saved-family-business/?utm_source=reddit/ submitted by /u/fortune [link] [comments]
- I was told AI was only going to help big business. My father is in his 80s and uses Gemini every morning.by /u/Wise-Cardiologist-31 (Artificial Intelligence) on May 15, 2026 at 3:30 pm
I was on a call with a potential business partner last week when he said something I keep hearing. "AI is really only going to help big business. The small people are going to get left behind." I let it sit for a second. Because here is what he did not know. My father is in his 80s. He uses Gemini every morning. I set it up with his calendar so it reads him his day. His appointments, what time he needs to be where, a quote to start the morning. He talks to it. He looks forward to it. He told me last week he is going to start asking it for lottery numbers, and I am pretty sure he was only half joking. This is a man who came up before personal computers were in homes. And here he is, in his ninth decade of life, in conversation with an AI before breakfast. That is not big business. That is my dad. I have used story-based AI with my own children. I have watched parents of nonverbal kids use the same tools and get reactions from their child that they do not get any other way. A story, a voice, a character that meets the child where they are and waits with them. I am not going to pretend that fixes everything. It does not. But for a parent who has spent years searching for a way in, a small door opens. That matters. The research backs this up. A study out of Seongdong-gu in Korea followed 80 community-dwelling older adults using a conversational AI called CLOVA CareCall for biweekly check-ins. After 31 weeks, their depression scores went down and their memory scores went up. Over 90 percent said they wanted to keep going. Loneliness is not a soft problem. It raises the risk of dementia by 31 percent, Alzheimer's by 14 percent, and vascular dementia by 17 percent. That is comparable to the impact of smoking. A phone call from an AI is not a replacement for a phone call from a grandchild. Nobody is arguing that. But for the senior who is not getting either, the AI is the difference between a quiet apartment and a connected morning. The guy I was talking to saw the headlines about enterprise AI, the billion-dollar deals, the layoffs, the productivity stats, and reached the conclusion most people are reaching. AI is a tool the powerful are using to get more powerful. I understand the read. I just think it is incomplete. Because while the headlines are about enterprise, the real adoption is happening in homes. Parents using AI to plan meals, manage the family calendar, take some of the invisible labor off their plates. Seniors using it to feel less alone. Kids learning at their own pace with patience no overworked teacher can offer to thirty students at once. People with disabilities accessing a world that was not built for them. These are not edge cases. These are the use cases. The boom is not only happening in conference rooms. It is happening in living rooms. Curious if anyone else has watched AI quietly help someone in their family the headlines do not talk about. Would like to hear it. submitted by /u/Wise-Cardiologist-31 [link] [comments]
- Built a luxury AI influencer from scratch in 30 days. Got a real brand deal. Here is what I learned.by /u/NickyRaZz (Artificial Intelligence (AI)) on May 15, 2026 at 3:10 pm
*I want to share something I built because I think it is genuinely useful for anyone interested in AI content.* *Six weeks ago I started an experiment.* *Could one person with a laptop build a photorealistic luxury AI influencer from scratch with zero budget?* *The answer surprised me. Here is exactly what I did.* *Process:* *Used AI image generation tools*, u*sed AI video generation tools*, *Edited with an editing program*, *Distributed on Instagram* *What happened in 30 days:* *Built a photorealistic character*, g*enerated campaign quality content*, *landed first brand deal*, *Delivered professional UGC* *Biggest lessons:* *Face consistency is everything*, p*ersonality content outperforms pure aesthetics*. *Brand deals come faster than expected*. *Distribution is the only real challenge* *Happy to answer any questions about the process or results.* submitted by /u/NickyRaZz [link] [comments]
- Built a self-hosted contextual bandit appliance in Rust. Deployed it against a live AI trading product. Found two bugs in my own configuration before I found any in the runtime.by /u/Covert-Agenda (Artificial Intelligence) on May 15, 2026 at 2:52 pm
I've been working on two open-source projects: Lycan — a small graph execution language with strategy nodes as a first-class primitive (multiple implementations of the same contract, runtime learns weights from outcome feedback). Compiles to a binary graph, executed by a Rust runtime. No LLM in the hot path. Syntra — a self-hosted Docker/API appliance that serves compiled Lycan capsules. Multi-tenant, shadow-mode-first, contextual learning perontextKey, persistent filesystem store, audit/decision/feedback logs separated. Includes an MVP YAML authoring layer so you don't have to write the underlying Lisp. The use case I care about: repeated decisions where the best option depends on context and the outcome arrives later. LLM model routing, retry/timeout policy, queue selection, threshold tuning, anything where you'd reach for a contextual bandit but don't want to stand up a Python ML platform to do it. I'm dogfooding it against my own product (a public AI stock-debate panel with 30-day market-resolved outcomes, MoEFolio.ai). The first surprise wasn't from the runtime; it was that my contextKey schema was collapsing all sectors into unknown one because my sector lookup only resolved symbols from one of three input paths. The bandit was nominally 5-dimensional but effectively 2-dimensional, learning a cross-sector average that meant nothing. Fixing the data pipeline, not the algorithm, is most of the work in adaptive systems. Apache-2.0, very early, would love eyes from anyone who's worked on bandits in production. github.com/SectorOPS/Lycan github.com/SectorOPS/Syntra submitted by /u/Covert-Agenda [link] [comments]
- Father of VR Jaron Lanier on the AI future where humans get paid to be creativeby /u/JMarty97 (Artificial Intelligence (AI)) on May 15, 2026 at 2:47 pm
Podcast episode with Jaron Lanier, pioneer of virtual reality and scientist at Microsoft Research. He proposes a radically different way of thinking about AI, and unpacks its consequences from AI safety to the future of the economy. Highlights: The case for thinking of AI not as an alien intelligence, but rather as a collaboration of human data How this reframe helps you understand the failures of current AI systems, and why so many of the industry's most powerful figures seem to be losing their grip on reality A practical approach to AI safety inspired by multi-factor authentication in cybersecurity Why universal basic income is unstable, and why a creativity economy (where people earn from their contributions to AI) could be a better way of distributing the benefits of AI How to be an optimist about technological progress while acknowledging the risks and being critical of certain developments Why history gives us the most rational grounds for optimism about our future with AI submitted by /u/JMarty97 [link] [comments]
- If an obscure 1980s paradox is any guide, AI may be about to hit a huge tipping pointby /u/_fastcompany (Artificial Intelligence) on May 15, 2026 at 2:29 pm
There’s an old joke among economists that goes like this: “You can see the computer age everywhere but in the productivity statistics.” I didn’t say it was a funny joke. But when labor economist Robert Solow originally wrote those words in 1987, they were certainly true. Personal computers, corporate mainframes, and the first vestiges of the modern internet were all anyone could talk about. Yet productivity wasn’t budging. These whizzy technologies, in short, weren’t earning anyone any money. The phenomenon became known as Solow’s Paradox. Of course, we all know how that story ended. By the mid-1990s, productivity was on a tear, and tech was making lots of people fabulously wealthy. And (despite a subsequent crash and recovery), tech is now the linchpin of the modern economy. Today, AI is following a similar path. And new data suggests that a similarly massive productivity–and wealth–tipping point may be just around the corner. submitted by /u/_fastcompany [link] [comments]
- Found OpenHuman on Product Hunt this week and it genuinely made me rethink AI agents a bitby /u/Apart-Ad-9952 (Artificial Intelligence) on May 15, 2026 at 2:25 pm
I’ve been testing a lot of AI agent setups recently and honestly most of them start feeling the same after a while. The first hour is usually impressive the demos look smooth, the workflows seem smart, and it feels like things are moving insanely fast in this space. But after actually trying to use some of these systems longer term, I keep running into the same issue over and over again memory and continuity still feel pretty rough. A few days ago I was scrolling through Product Hunt and noticed OpenHuman trending there, so I ended up trying it mostly out of curiosity. I expected another complicated setup with a bunch of moving parts but the experience actually felt a lot simpler than most of the agent frameworks I’ve tested recently. What stood out to me wasn’t even the agent part itself. It was the fact that conversations and context felt more persistent without me constantly rebuilding everything from scratch every session. I’ve played around with OpenClaw and Hermes agents before too, and while those are interesting technically they always felt more experimental than practical for how I personally use AI tools day to day. OpenHuman felt more focused on continuity and usability instead of just showing autonomous workflows in a demo video. Still early obviously, and I’m sure there’s a lot that still needs improvement but it’s one of the first AI agent tools in a while that actually made me think more seriously about where long-term AI memory is heading. submitted by /u/Apart-Ad-9952 [link] [comments]























96DRHDRA9J7GTN6